Dr. Gregory Pond
Cancer clinical trials have evolved rapidly in recent years as investigators integrate an expanding body of knowledge into the design and analysis of clinical trials. Coupled with an increased importance on efficiency and availability of large data warehouses, there is an even greater need for identifying and using appropriate statistical methodologies. The focus of Dr. Gregory Pond’s research interests is in the statistical methodologies and analysis of cancer clinical trials, with an aim to facilitate the translation of scientific discoveries into the clinic.
- Investigator II, OICR;
- Associate Professor, Department of Oncology, McMaster University;
- Research Scientist, Escarpment Cancer Research Institute;
- Faculty Biostatistician, Ontario Clinical Oncology Group (OCOG).
- Clinical trials;
- Big data;
- Survival methodology.
Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, Di Lorenzo G, Bellmunt J.
Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.
J Urol. February 2016. 195(2), 277–82. doi: 10.1016/j.juro.2015.07.111. PMID: 26292040.
Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ.
The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer.
Eur Urol. 2014 Jan; 65(1):3-6. doi: =10.1016/j.eururo.2013.09.024. Epub 2013 Oct 5. PMID: 24120464
O’Leary E, Seow H, Julian J, Levine M, Pond GR.
Data collection in cancer clinical trials: Too much of a good thing?
Clin Trials. 2013 Aug; 10(4):624-32. doi: 10.1177/1740774513491337. PMID: 23785066.
Pond GR, Abbasi S.
Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Clin Trials. 2011 Jun;8(3):260-9. doi: 10.1177/1740774511401764. Epub 2011 Apr 20.
Statistical issues in the use of dynamic allocation methods for balancing baseline covariates.
Br J Cancer. 2011 May 24;104(11):1711-5. doi: 10.1038/bjc.2011.157. Epub 2011 May 3.
Gan HK, Grothey A, Pond GR, Moore MJ, Siu LL, Sargent D.
Randomized Phase II Trials: Inevitable or Inadvisable?
J Clin Oncol. 2010 May 20; 28(15):2641-7. doi: 10.1200/JCO.2009.26.3343. Epub 2010 Apr 20.
Previous experience and education
- PhD, Biostatistics, University of Toronto;
- M.Sc., Statistics, Simon Fraser University (SFU);
- Senior P.Stat., Accredited as Professional Statistician, Statistical Society of Canada;
- Biostatistician, Princess Margaret Cancer Centre;
- Biostatistician, Mayo Clinic.
- McMaster University – Dr. Gregory Pond
- Ontario Clinical Oncology Group
- Escarpment Cancer Research Institute